Radiopharm Theranostics (RADX) Stock Price, News & Analysis

Company Overview

Radiopharm Theranostics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types. Radiopharm Theranostics collaborates with academic centers and contract development and manufacturing organizations to advance candidates from preclinical studies through clinical trials, with an emphasis on safety, efficacy and scalable production.

Headquartered in Alpharetta, Georgia, Radiopharm Theranostics conducts operations in the United States and is positioning itself for expansion into select international markets. Its management team brings together professionals with deep expertise in radiopharmaceutical chemistry, nuclear medicine and oncology drug development, underscoring the company’s commitment to advancing next-generation diagnostic and therapeutic solutions.

Key Stats

• Today's Range: $6.60 to $7.74
• 50-Day Range: $4.14 to $7.10
• 52-Week Range: $3.50 to $50.82
• Volume: 38,201 shs
• Average Volume: 43,965 shs
• Market Capitalization: $55.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Strong Buy

RADX Stock Analysis - Frequently Asked Questions

How have RADX shares performed this year?

Radiopharm Theranostics' stock was trading at $4.00 at the start of the year. Since then, RADX stock has increased by 77.5% and is now trading at $7.10.

Who are Radiopharm Theranostics' major shareholders?

Top institutional investors of Radiopharm Theranostics include Affinity Asset Advisors LLC (0.45%) and PNC Financial Services Group Inc. (0.10%).

How do I buy shares of Radiopharm Theranostics?

Shares of RADX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/17/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RADX
• CIK: 1949257
• Web: www.radiopharmtheranostics.com
• Phone: 61-3-9824-5254
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Radiopharm Theranostics: $15.00
• High Price Target: $18.00
• Low Price Target: $12.00
• Potential Upside/Downside: +111.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,880,000
• Free Float: N/A
• Market Cap: $55.95 million
• Optionable: N/A
• Beta: N/A